SCHEMBL1151780

SCHEMBL1151780

OCCC(c1ccc(O)cc1)C(c1ccccc1)c1ccc(O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
HSD17B10 Q99714 2/20 0.47
ALDH1A1 P00352 2/20 0.47
TRPA1 O75762 2/20 0.44
ESR1 P03372 3/20 0.44
TDP1 Q9NUW8 3/20 0.44
SLC6A2 P23975 2/20 0.44
SLC6A3 Q01959 2/20 0.44
CYP1A2 P05177 1/20 0.44
PGR P06401 1/20 0.44
CHRM2 P08172 1/20 0.44
CYP3A4 P08684 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
AR P10275 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.44
CHRM1 P11229 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44
DRD1 P21728 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1151793 1.00 LMNA (0.47) LMNAHSD17B10ALDH1A1TRPA1ESR1
SCHEMBL11205024 0.92 LMNA (0.42) LMNAHSD17B10ALDH1A1TRPA1ESR1
SCHEMBL1152470 0.84 LMNA (0.42) LMNAHSD17B10ALDH1A1ESR1TDP1
SCHEMBL1151700 0.84 ESR1 (0.47) LMNAHSD17B10ALDH1A1ESR1TDP1
SCHEMBL5604418 0.80 LMNA (0.53) LMNAHSD17B10ALDH1A1TRPA1ESR1
SCHEMBL10774365 0.78 ESR1 (0.48) LMNAALDH1A1ESR1TDP1SLC6A2
SCHEMBL503028 0.77 IDO1 (0.56) LMNAHSD17B10ALDH1A1ESR1TDP1
SCHEMBL17995329 0.77 IDO1 (0.56) LMNAHSD17B10ALDH1A1ESR1TDP1
SCHEMBL14163315 0.77 IDO1 (0.56) LMNAHSD17B10ALDH1A1ESR1TDP1
SCHEMBL25079595 0.75 ESR1 (0.60) LMNAHSD17B10ALDH1A1ESR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2013-10-31 US disclosed
US-8475804-B2 Compositions and methods for treatment of filovirus-mediated diseases U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) 2013-07-02 US disclosed
US-20110028564-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES ZALICUS INC. 2011-02-03 US disclosed
WO-2008133884-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS COMBINATORX, INCORPORATED (US) 2008-11-06 WO disclosed
US-4996225-A Antitumor agents FARMOS GROUP LTD. (FI) 1991-02-26 US disclosed
US-4696949-A ANTITUMOR AGENTS, ANTIESTROGENS FARMOS GROUP LTD. (FI) 1987-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028564-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES FLNA, FLNB, PIGS LMNA 156/4885HSD17B10 3104/4885ALDH1A1 3453/4885
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES FLNA, FLNB, PIGS LMNA 156/4885HSD17B10 3104/4885ALDH1A1 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.